Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions is well positioned for strong growth in the biopreservation and cell processing market, with the opening of the Aby J. Mathew Center for Biopreservation Excellence providing a showcase for its full product portfolio and potential for developing next-generation products. With a projected sales per share of $2.19, EV/Revenue multiple of 13.3x, and net cash of $2.42 per share, our 12-month target price of $32 is supported by a comparable universe analysis and may be subject to risks such as lower-than-projected growth, inability to secure additional customers, fluctuation of sales in emerging markets and foreign exchange rates, and potential dilution risk.

Bears say

BioLife Solutions is facing strong competition in the cell and gene therapy ("CGT") industry resulting in decreased sales and revenue. Their cash flow has decreased from $7.6M in 2Q25 to $6.1M in 3Q25, indicating a potential slowdown in operations and potential financial difficulty in the future. The company's reliance on a single product, CryoStor, also increases its vulnerability to market changes and potential disruptions in the bioproduction industry.

BioLife Solutions (BLFS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioLife Solutions (BLFS) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.